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Abstract 
Background 
Dementia with Lewy Bodies (DLB) has existed as a formal consensus diagnosis since 
1996 and is defined by dementia and the core features parkinsonism, visual 
hallucinations and cognitive fluctuations. The original consensus criteria had low 
sensitivity (20-60%) although the specificity was satisfying. (80-100%) From 2005 the 
additional suggestive features rapid eye movement (REM) sleep behaviour disorder 
(RBD), low uptake on Dopamine Transporter Scan (DaTSCAN ) and neuroleptic 
sensitivity have been included to improve sensitivity of the clinical diagnosis. The 
nosological status of DLB is still discussed, and the frequencies of DLB, and of RBD 
and other sleep disturbances in DLB, are not known.
Objectives 
In our first paper we sought to find the frequency of DLB in the Dementia Study of 
Western Norway, (The DemVest-Study) applying the revised clinical diagnostic DLB-
criteria. We compared the frequency of DLB in our cohort applying both the new 
revised and the original consensus criteria for diagnosing DLB to find if the new 
criteria are more sensitive. 
In the second paper we compared the frequency of sleep disturbances in Lewy Body 
Dementia (LBD) as compared to Alzheimer’s Dementia (AD) and healthy controls.  
In the third paper we examined how the core and suggestive features of DLB were 
distributed among all individuals with mild dementia to find empirical support for 
diagnosing DLB as an own diagnostic entity and to find cut- off values for core and 
suggestive features designating DLB.  
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Methods 
All referrals to 5 specialists out patient clinics doing dementia work up in Western 
Norway were screened during a 2 year inclusion period. Particular care was taken to 
screen all included patients for the core and suggestive features of DLB. We offered 
inclusion to everybody presenting with a first time diagnosis of mild dementia with a 
MMSE score  20. Exclusion criteria were normal cognition or mild cognitive 
impairment, severe dementia, organic or functional psychosis and a diagnosis of 
severe or terminal physical illness.  
For the first paper dementia was diagnosed according to DSM-IV criteria and DLB 
according to both the 1996 and 2005 criteria. For the second paper we applied the 
Mayo Sleep Questionnaire (MSQ) and the Neuropsychiatric Inventory (NPI) to screen 
for sleep disturbances. Healthy elderly subjects from the Mayo Clinic Study of Aging 
were available for comparison. 
In the third paper we used a two step cluster analysis to classify persons with mild 
dementia according to continuous scores on scales for the DLB symptoms; 
hallucinations, fluctuations, parkinsonism and RBD.
Results 
196 subjects were included in the first paper and of these 20 % had DLB according to 
the revised consensus criteria. We compared the 1996 criteria to the 2005 criteria and 
found a 25% increase in patients fulfilling the probable DLB category with the new 
criteria. The proportion with DLB did not differ according to age bands and dementia 
severity. (CDR) 
In the second paper 155 patients with mild dementia who had a caregiver who was 
also their bed-partner and 420 age matched controls without dementia were included. 
Participants with Lewy Body Dementia, i.e. DLB and PDD combined, had 
significantly more sleep disturbances than those with AD (89% vs. 64%, p=0.008) 
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particularly regarding RBD. (39% vs. 9%, p<0.0005) Having any sleep disturbance 
correlated with both anxiety (p=0.02) and depression. (p=0.03)  
In the third paper we included 139 persons with mild dementia who had a complete 
data set for hallucinations, parkinsonism, fluctuations and RBD. Four clusters were 
identified, one containing persons with high scores on scales for hallucinations, 
fluctuations and motor parkinsonism (the “LBD-cluster”). A distinct cognitive profile 
was found for this cluster, with more marked visuospatial deficits. The three other 
clusters included subjects with very mild or no DLB symptoms (“non LBD-cluster”) 
and two cluster with pronounced RBD or Visual hallucinations. (VH)  Cut-off scores 
on scales for the DLB symptoms were suggested based on the scores in the four 
clusters. 
Conclusions 
DLB is the second most frequent primary dementia in specialist out patients’ clinics in 
Western Norway and accounts for 20% of the mild dementia population in this setting. 
The revised clinical diagnostic criteria have increased sensitivity as compared to the 
original criteria. LBD patients have significantly more sleep disturbances as compared 
to AD supporting the incorporation of RBD in the clinical diagnostic criteria for DLB. 
Sleep disturbances in mild dementia is related to anxiety and depression underlining 
their clinical importance. The core and suggestive features of DLB cluster in our 
sample of persons with mild dementia, thereby supporting the validity of DLB as a 
distinct diagnostic entity. The differentiation of DLB from other types of mild 
dementias can be made according to suggested cut-off values on scales for the core 
and suggestive DLB features 
9 
List of publications
1. Aarsland D, Rongve A, Nore SP, Skogseth R, Skulstad S, Ehrt U, Hoprekstad 
D, Ballard C: Frequency and case identification of dementia with lewy bodies 
using the revised consensus criteria. Dement Geriatr Cogn Disord 2008;26:445-
452. 
2. Rongve A, Boeve BF, Aarsland D: Frequency and correlates of caregiver-
reported sleep disturbances in a sample of persons with early dementia. J Am 
Geriatr Soc 2010;58:480-486. 
3. Rongve A, Bronnick K, Ballard C, Aarsland D: Core and suggestive symptoms 
of dementia with lewy bodies cluster in persons with mild dementia. Dement 
Geriatr Cogn Disord 2010;29:317-324. 
List of other publications 
1. Rongve A, Aarsland D, Ballard C. Current perspectives in dementia with Lewy 
bodies. Aging Health 2006;Vol. 2:461-472. Review. 
2. Rongve A, Aarsland D: Management of Parkinson's disease dementia: Practical 
considerations. Drugs & Aging. 2006;23(10):807-22. Review. 
3. Skogseth R, Mulugeta E, Ballard C, Rongve A, Nore S, Alves G and Aarsland 
D. Neuropsychiatric correlates of CSF biomarkers in Alzheimer’s disease; 
Dement Geriatr Cogn Disord 2008;25:559-563 
4. Biringer E, Rongve A and Lund A: A Review of Modern Antidepressants’ 
Effects on Neurocognitive Function; Current Psychiatry Reviews 2009;5:164-
174
5. Sonnesyn H, Nilsen DW, Rongve A, Nore S, Ballard C, Tysnes OB, Aarsland 
D: High prevalence of orthostatic hypotension in mild dementia. Dement 
Geriatr Cogn Disord 2009;28:307-313. 
10 
Contents 
SCIENTIFIC ENVIRONMENT ......................................................................................................2
ABBREVIATIONS.....................................................................................................................4
ABSTRACT.......................................................................................................................... 6
BACKGROUND .......................................................................................................................6
OBJECTIVES ..........................................................................................................................6
METHODS ..............................................................................................................................7
RESULTS ...............................................................................................................................7
CONCLUSIONS .......................................................................................................................8
LIST OF PUBLICATIONS ...........................................................................................................9
LIST OF OTHER PUBLICATIONS ................................................................................................9
GENERAL INTRODUCTION .................................................................... 13
BACKGROUND .....................................................................................................................13
HISTORICAL BACKGROUND...................................................................................................15
NOMENCLATURE AND CLINICAL DIAGNOSTIC CRITERIA FOR DLB............................................16
CLINICAL DIFFERENTIAL DIAGNOSIS ......................................................................................17
EPIDEMIOLOGY ....................................................................................................................18
MOLECULAR PATHOLOGY.....................................................................................................20
NEUROPATHOLOGY..............................................................................................................21
GENETICS............................................................................................................................22
BIOMARKERS.......................................................................................................................22
THE CLINICAL PROFILE OF DLB ............................................................................................23
PHARMACOLOGICAL TREATMENT..........................................................................................27
NON-PHARMACOLOGICAL TREATMENT ..................................................................................29
DESIGN ...............................................................................................................................31
INCLUSION CRITERION ..........................................................................................................31
EXCLUSION CRITERIA ...........................................................................................................31
11 
DEMENTIA DIAGNOSIS ..........................................................................................................32
CLINICAL EXAMINATION ........................................................................................................32
NEUROPSYCHIATRIC ASSESSMENT........................................................................................33
NEUROPSYCHOLOGICAL EXAMINATION..................................................................................34
SLEEP ASSESSMENT ............................................................................................................35
DIAGNOSING CORE AND SUGGESTIVE SYMPTOMS OF DLB......................................................37
BIOMARKERS.......................................................................................................................38
STATISTICS..........................................................................................................................39
ETHICS AND LEGAL ISSUES...................................................................................................40
RESULTS .............................................................................................................................. 41
PAPER 1..............................................................................................................................43
PAPER 2..............................................................................................................................43
PAPER 3..............................................................................................................................44
DISCUSSION ................................................................................................................... 45
FINDINGS IN CONTEXT ..........................................................................................................45
THE FREQUENCY OF DLB.....................................................................................................45
THE PROPORTION OF DLB ACROSS AGE BANDS ....................................................................48
PROPORTION OF DLB ACROSS SEVERITY GROUPS ................................................................50
COMPARING THE TWO SETS OF CLINICAL DIAGNOSTIC CRITERIA .............................................52
GENDER ..............................................................................................................................53
THE FREQUENCY OF SLEEP DISTURBANCES AND CLINICAL CORRELATES.................................53
FOUR CLUSTERS REVEALED IN MILD DEMENTIA......................................................................56
DIFFERENT COGNITIVE PROFILES IN CLUSTERS ......................................................................57
THRESHOLDS FOR CORE AND SUGGESTIVE FEATURES OF DLB ..............................................58
THE DEFINITION OF COGNITIVE FLUCTUATIONS.......................................................................58
CROSS SECTIONAL DESIGN...................................................................................................59
CASE SELECTION, RECRUITMENT AND POTENTIAL BIAS ..........................................................59
METHODS OF MEASUREMENT................................................................................................60
12 
CONFOUNDING FACTORS......................................................................................................61
CONCLUSIONS .....................................................................................................................62
IMPLICATIONS FOR CLINICAL PRACTICE .................................................................................62
DIRECTIONS FOR FUTURE RESEARCH ....................................................................................63
REFERENCES................................................................................................................. 64
APPENDIX.......................................................................................................................... 76
REVISED CRITERIA FOR THE CLINICAL DIAGNOSIS OF DLB .....................................................76
TABLE 1 PATHOLOGICAL AND CLINICAL COHORTS REPORTING THE FREQUENCY OF DLB ........77
TABLE 2 COMMUNITY BASED STUDIES REPORTING THE FREQUENCY OF DLB..........................78
TABLE 4 STAGING OF LEWYBODY PATHOLOGY IN THE HUMAN BRAIN......................................80
TABLE 5 VALIDATION STUDIES FOR PATHOLOGICAL CRITERIA ................................................81
TABLE 6. GENE MUTATIONS AND THEIR CLINICAL PHENOTYPES..............................................82
TABLE 7 DEMOGRAPHICS AND BASELINE CHARACTERISTICS OF INCLUDED PARTICIPANTS.......83
LEVELS OF EVIDENCE CLASS I-IV.........................................................................................84
PAPERS I-III 
ERRATA
13 
General introduction       
This thesis is based on the baseline data from the Dementia Study of Western Norway, 
(the Dem-Vest study) a clinical dementia cohort study, and consists of 3 published 
papers and this summary. The focus has been on Dementia with Lewybodies (DLB). 
The literature review constituting the first part of the summary is based on publications 
registered in the PubMed database. For the chapter on the frequency of DLB we tried 
to include all publications available, otherwise we choose the most recent or relevant 
citations. 
Background 
The aging of the population is reaching the shores of the world as we speak and has 
become a major concern for politicians worldwide due to the dramatic increases in 
costs for the care of the elderly. In the western developed world the elderly population 
is growing fast and the oldest age group (85+) is the fastest growing.(WHO, 2010) 
Statistics Norway has estimated that this effect will kick in at full speed during the 
next decades as today 617000 persons 67 years or older are living in our country and 
in 2060 the number will have increased to 1.5millions. The most common causes of 
dementia are AD, DLB and Vascular Dementia.(VaD) In Norway it is estimated that at 
present about 60000 - 70000 people have dementia and the number is expected to rise 
to 94000 in 2030 and to 142000 in 2050.(Hjort & Waaler, 2010) As still no cure is 
available the expenses due to dementia in the society will increase dramatically. 
Dementia is already regarded more expensive to society than all cancer and heart 
disease together.(Reuters, 2010) Societal expenses in dementia are mainly due to long 
term admissions to nursing homes. The Western societies are now facing the start of 
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these challenges concerning increasing costs and lack of manpower to care for persons 
with dementia.  
The most frequent neurodegenerative conditions are Alzheimer’s Disease (AD), 
Dementia with Lewybodies (DLB) and Parkinson’s Disease. (PD) These three 
diagnoses can both clinically and pathologically be viewed as existing on a continuum 
or alternatively as overlapping categories. Dementia with Lewy Bodies (DLB) is part 
of a group of neurodegenerative disorders termed the -synucleinopathies. (table 1) 
These are characterized neuropathologically by eosinophilic intraneuronal Lewy 
bodies composed of mainly -synuclein and ubiquitin located in affected areas of the 
central and peripheral nervous system. They include disorders like Parkinson’s disease 
and Multiple System Atrophy.(Galvin, Lee, & Trojanowski, 2001) Recently published 
studies from Swedish colleagues found that persons with DLB have more impaired 
quality of life and use more resources as compared to persons with AD, thus 
underlining the clinical importance of the condition. (Bostrom, Jonsson, Minthon, & 
Londos, 2006, 2007) 
Table 1 The -synucleinopathies 
Name Characteristic features 
Lewy Body Dementia  Parkinsonism, visual hallucinations, fluctuations 
and RBD 
Parkinson’s Disease  Tremor, rigidity, akinesia and gait disturbance 
Parkinson’s Disease Dementia Dementia developed after more than 1 year of 
motor symptoms 
Multiple System Atrophy Autonomic dysfunction, parkinsonism and ataxia 
Idiopathic REM sleep behaviour 
Disorder 
Acting out dream content during REM sleep 
Pure autonomic failure  Orthostatic hypotension, constipation, sweating 
and impotence 
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Historical background 
Fritz Heinrich Lewy (1885-1950) discovered what was later named “Lewybodies” 
during his research on parkinsonism in 1912. The designation Lewybody was 
suggested by Tretiakoff in his thesis from 1919. In 1923 Lewy published his 
monograph concerning 43 patients with parkinsonism of which 21 were demented. 
(Alafuzoff, et al., 2009; Rodrigues, et al. 2010) The recognition of Dementia with 
Lewy Bodies (DLB) as an independent neurodegenerative entity grew after Okazaki 
described two clinical cases with dementia, disorientation, hallucinations and profound 
motor symptoms with rapid progression. The autopsy confirmed the presence of 
cortical Lewy bodies which morphologically were indistinguishable from those seen in 
the brains of PD patients. Lewy bodies were distributed widely inn the cortical areas. 
Senile plaques and tangles were not observed and as such distinguished these cases 
from AD.(Okazaki, Lipkin, & Aronson, 1961) These results were first presented in 
1958 and linked cortical Lewy bodies and dementia. In 1976-1980 several series of 
clinical case studies were published from Japanese groups and in 1984 Kosaka et al. 
proposed the name diffuse Lewy Body disease.(Kosaka, Yoshimura, Ikeda, & Budka, 
1984) 
The triad of dementia and parkinsonism and psychosis was from the start considered 
the core syndrome. Later fluctuating confusion, frequent falls, neuroleptic sensitivity 
and syncope were added. Cognitive deficits that differed from AD were described i.e. 
relatively more pronounced impairment of attention and executive and visuospatial 
functions compared to less severe memory impairment. The significance of the 
underlying pathology was controversial regarding the relative contribution from 
Lewybody pathology and AD pathology with plaques and tangles and this was 
reflected the diverse nomenclature applied for this condition before the consensus 
criteria were first published in 1996. In 1998 Spillantini et al. published their paper 
stating that alpha- synuclein (S) is the main constituent of Lewybodies, designating a 
new group of neurodegenerative disorders named the -synucleinopathies.(Spillantini, 
Crowther, Jakes, Hasegawa, & Goedert, 1998) 
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Nomenclature and clinical diagnostic criteria for DLB 
Uncertainty regarding the contribution of underlying pathology to the clinical picture 
resulted in different groups publishing different names for the same disorder. Some 
groups regarded the cortical Lewy Bodies as the major contributor to the clinical 
picture and designed names like Diffuse Lewy Body Disease,(Kosaka, et al., 1984) 
Dementia with cerebral Lewy bodies(Eggertson & Sima, 1986) or Senile dementia of 
Lewy body type.(Perry, Irving, Blessed, Fairbairn, & Perry, 1990) The importance of 
AD pathology was stressed by other groups suggesting names like Alzheimer’s disease 
with Parkinson’s disease changes,(Ditter & Mirra, 1987) Alzheimer disease with 
incidental Lewy bodies(Joachim, Morris, & Selkoe, 1988) and Lewy Body variant of 
Alzheimer’s disease.(Hansen, et al., 1990)  
In 1991 The Nottingham group first proposed their clinical diagnostic criteria for what 
later became DLB  (Byrne, Lennox, Godwin-Austen, Lowe, & Mayer, 1991) and later 
the Newcastle group published their criteria in 1992.(I. G. McKeith, Perry, Fairbairn, 
Jabeen, & Perry, 1992) In 1995 the DLB consortium developed the first consensus 
criteria for a clinical diagnosis of DLB(I. G. McKeith, et al., 1996) characterized by 
dementia accompanied by the “core” features fluctuating cognition and consciousness, 
spontaneous features of parkinsonism and visual hallucinations, with additional 
“supporting” features like frequent falls, syncope, transient loss of consciousness, 
systematized delusions and severe sensitivity to treatment with antipsychotic drugs. 
The criteria have been validated and later updated, and in the revised version of the 
international consensus criteria from 2005 “suggestive” features like RBD and a 
positive CIT-SPECT or PET scan and neuroleptic sensitivity were added, see appendix 
for criteria.(I. G. McKeith, et al., 2005)  
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Clinical differential diagnosis 
Being the two most common forms of primary degenerative dementia DLB and AD 
can clinically sometimes be hard to reliably differentiate. The clinical diagnosis of 
DLB is based on the clinical interview with the person with dementia and the caregiver 
plus a clinical examination and a set of cognitive tests. Supplemental tests include 
Magnetic Resonance Imaging (MRI) to exclude other intracranial pathology and 
DaTSCAN to confirm the diagnosis. To make a reliable DLB diagnosis the clinician 
will have to screen for both core, suggestive and supportive features of the disease. A 
cognitive profile with executive and visuospatial impairment and preserved memory 
and language can aid in the differential diagnosis between DLB and AD as can results 
from the CSF analysis, MRI scan and in particular DaTSCAN as described in the 
proposed new and updated diagnostic research criteria for AD(Dubois, et al., 2007) 
and the revised DLB criteria.(I. G. McKeith, et al., 2005) 
DLB can be differentiated from Parkinsons Disease Dementia (PDD) based on the 1 
year rule, i.e. in DLB motor symptoms can start before, i.e. up to one year before 
dementia. If motor parkinsonian symptoms started more than 1 year before dementia 
the condition will be diagnosed as PDD. Clinicians will often find it difficult to 
determine the exact starting time of the different cognitive and neuropsychiatric 
symptoms as compared to motor symptoms. 
Vascular Dementia (VaD) and Frontotemporal Dementia (FTD) can in most cases be 
differentiated from DLB based on the clinical interview and examination and 
supplemental tests like MRI and a SPECT-scan. Vascular parkinsonism due to 
vascular damage in the basal ganglia can be difficult to differentiate from 
parkinsonism in PD, PDD and DLB, although a MRI scan can contribute. When 
diagnosing DLB clinically the clinician needs to have other less frequent conditions 
like the Parkinson plus syndromes in mind: 
Progressive Supranuclear Palsy (PSP) is a tauopathy, characterized by axial 
parkinsonism, early tendency to fall backwards and impaired vertical eye movements.  
PSP can be complicated by subcortical dementia and is sometimes hard to differentiate 
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from another tauopathy, namely frontotemporal dementia (FTD). Corticobasal 
degeneration (CBD) is a rare tauopathy characterized by more severe motor 
impairment with apraxia and agnosia with poor response to L-DOPA. Multiple system 
atrophy (MSA), another -synucleinopathy, is characterized clinically by the early 
development of ataxia, autonomic failure and symmetrical parkinsonism with rigidity 
and bradykinesia without tremor. Patients have poor response to L-dopa treatment and 
poor prognosis. MRI can in many cases inform the clinical diagnosis. In frail elderly 
people symptoms like parkinsonism and impaired cognition can be caused by 
neuroleptic medication and thus a drug history must be taken in the diagnostic process. 
Epidemiology 
Dementia with Lewybodies (DLB) was first considered to be a rare condition. Now 
most authors agree that DLB is the second most common form of neurodegenerative 
dementia comprising 15-20% of the primary degenerative dementias. The revised 
clinical diagnostic criteria from 2005 have not yet been applied in any population 
based or clinical epidemiological study.  
In previous clinical and population based dementia-cohort studies applying the original 
criteria from 1996 the reported proportion with DLB ranges from 0% to 
30.5%.(Rongve, Aarsland, & Ballard, 2006; Zaccai, McCracken, & Brayne, 2005; 
Aarsland, et al., 2008) (See table 1&2 in the Appendix for a complete  overview of 
studies) Few population based epidemiological findings have been published and only 
two studies present follow up data with pathological verification of the 
diagnosis.(Matsui, et al., 2009; Pathological correlates of late-onset dementia in a 
multicentre, community-based population in England and Wales. Neuropathology 
Group of the Medical Research Council Cognitive Function and Ageing Study (MRC 
CFAS, 2001) More recently a community based survey from Japan, the Hisayama 
Study, was presented finding DLB in 10.6 % of cases in neuropathological confirmed 
cases and pure DLB neuropathologically in 4.4% of the dementia cases, and thus 
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confirming previous findings that DLB might be less and VaD more prevalent in 
Asian countries as compared to Western countries. The frequency of pure VaD in this 
study was 29.5%.(Matsui, et al., 2009)  
The Islington Community Study of Dementia from North London UK found a high 
prevalence of dementia of 9.86% in the age group of 65 years and older with 9.7% of 
this dementia cohort having probable DLB and 30.5% possible or probable DLB 
combined.(Stevens, et al., 2002)  Diagnosis was based on a validated screening 
instrument of dementia and an unstructured interview of a caregiver. A diagnosis of 
DLB was made only if the patient had progressive dementia with prominent visual 
hallucinations and either fluctuating cognition or spontaneous features of parkinsonism 
and thus patients with DLB without hallucinations were not included. On the other 
hand they did not limit the duration of parkinsonism before onset of dementia to a 
maximum of one year and therefore might have included also patients with Parkinson 
Disease Dementia (PDD).(Stevens, et al., 2002)  A health survey in the Kupio area in 
Finland of people 75 years and older found a dementia prevalence of 22% in their 
screened population. The proportion of DLB was 21.9% in this dementia cohort. This 
study used a structured clinical interview and examination. They collected information 
from carers but did not use a structured interview for this purpose and did not use 
instruments to detect and measure parkinsonism, fluctuating cognition, visual 
hallucinations and RBD.(Rahkonen, et al., 2003) 
These two studies, the Islington and Kuopio studies, provide the best estimate of the 
prevalence of DLB in the general population published this far and suggest that DLB  
accounts for about 10-22% of the dementias in the 65+ age group thus indicating that 
about 1% of the population over 65 years suffer from DLB.  Other population based 
studies performed with less stringent methods have found lower prevalence of DLB, 
see table 1 & 2 in Appendix.(de Silva, Gunatilake, & Smith, 2003; Herrera, Caramelli, 
Silveira, & Nitrini, 2002; Haan, et al., 2003; Yamada, Hattori, Miura, Tanabe, & 
Yamori, 2001; Yamada, et al., 2002; Zaccai, et al., 2005)  
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Only four incidence studies exist and report the incidence of DLB to lie between 0.7-
1.4 new cases for every 1000 persons per year. (de Lau, et al., 2004; Matsui, et al., 
2009) (Table 3 Appendix) In summary, only two community based epidemiological 
studies have specifically focused on the prevalence of DLB. None have applied the 
revised clinical criteria and applied specific instruments to detect core and suggestive 
features. Therefore the prevalence of DLB according to the latest criteria is not known. 
Molecular pathology 
The Lewy body diseases share aggregation of alpha-Synuclein (S) and formation of 
Lewy bodies as their common hallmarks of pathology. The normal structure and 
function of S is not well known although it is believed to be involved in synaptic 
plasticity.  Norwegian researchers have recently shed some light on possible 
pathogenic mechanisms finding in a mouse model that increased expression of S will 
inhibit synaptic reclustering after neurotransmitter release and thus inhibit 
neurotransmitter release in the synaptic cleft.(Nemani, et al. 2010)  Pathological 
phosphorylation and aggregation into toxic oligomers and pathological spread of 
oligomers from one neuron to adjacent neurons has been suggested as a possible 
mechanism for spreading the S-pathology within the CNS. (Danzer, Krebs, Wolff, 
Birk, & Hengerer, 2009) It has been shown that S produced intracellularly can be 
excreted in the extracellular space in a calcium dependent way and that extracellular 
S can decrease cell viability and amplify and propagate the Lewy related 
pathology.(Emmanouilidou, et al. 2010)  
Lewybodies are intraneuronal cytoplasmic, eosinophilic and spherical inclusion bodies 
composed of S and ubiquitin. They form the altered neurofilaments which 
accumulate after abnormal cleavage and phosphorylation of the S 
protein.(Cummings, 2004) Two morphologically distinct subtypes i.e. the brainstem 
and cortical Lewy body types have been described. Lewy bodies were thought 
originally to cause cell damage in the same way as the beta- amyloid plaques in AD 
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but are now hypothesised to represent the result of a well performed cell defence 
system to protect against more toxic species like the alpha-synuclein 
oligomers.(Tanaka, et al., 2004) 
Neuropathology 
Lewybodies and Lewy neuritis in brainstem, midbrain and cortical areas have been 
extensively studied and correlated to specific clinical features.(CG Ballard, Mohan, 
Patel, & Bannister, 1993) 3 out of every 4 patients with DLB in addition have 
Alzheimer pathology, although usually with fewer tangles than in AD.(Del Ser, 
Hachinski, Merskey, & Munoz, 2001; Merdes, et al., 2003) Different pathological 
staging-systems have been proposed by different authors regarding the staging of 
DLB, PDD and PD. First Kosaka in 1980 proposed to differentiate 3 subtypes of DLB 
pathologically; brainstem, transitional and cortical.(Kosaka, et al., 1984) The revised 
pathological consensus criteria now implement severity and distribution of both 
Alzheimer and Lewy pathology in the CNS according to these three 
subtypes.(Fujishiro, et al., 2008; I. G. McKeith, et al., 2005) 
Braak more recently have proposed criteria for staging the Lewybody pathology in 
Parkinsons Disease (PD) and others have proposed such models for DLB.(Leverenz, et 
al., 2008; Muller, et al., 2005) In Australia three distinctive groups have been 
described neuropathologically in dopa-responsive PD patients recruited and followed 
until death; One with younger onset PD and long duration of the disease with 
neuropathology corresponding to the Braak stages. The second with early malignant 
dementia dominant syndrome and severe neocortical disease as described in DLB. The 
third group with older onset, shorter survival and a more complex disease with 
additional pathologies and higher Lewybody loads in the brain.(Halliday, Hely, Reid, 
& Morris, 2008) (See table 4 and 5 in the Appendix)
According to Kurt Jellinger: “The neuropathology of PDD and DLB is similar without 
significant differences between cortical and subcortical Lewy bodies and the pattern of 
22 
synuclein pathology in the brainstem. There are topographic differences in nigral 
lesions, more frequent affection of the hippocampal CA 2/3 subareas and more severe 
diffuse amyloid plaque load in the striatum of DLB”.(Jellinger, 2009)   
Genetics 
The genetic underpinnings of PD have been studied extensively during the last decade 
based on studies in families with autosomal dominant parkinsonism. Several gene 
mutations and their miscoded proteins have been recognized and labelled PARK 1-16 
of which many have been given additional names. Both motor parkinsonism and 
dementia have been found to occur in the same families. Most DLB cases occur 
sporadically although families have been described having many affected members 
with gene alterations in different locations of which some overlap with PD. The gene 
encoding S, the - synuclein gene (SNCA) have been named PARK1 / PARK4 in 
PD.(Kurz, Schlitter, Larsen, Ballard, & Aarsland, 2006)  Three different mutations 
have been published in addition to duplication and triplication of the SNCA-gene and 
and two mutations in the gene encoding -synuclein have been described. (Table 6 in 
Appendix) In summary, more studies are needed to identify the genetic contributions 
to DLB. 
Biomarkers 
CIT-SPECT or DaTSCAN, the visualisation of the striatal dopamine transporter, a 
measure of the dopaminergic pre-synaptic nigro-striatal system, now has become 
established as a biomarker in DLB(O'Brien, et al., 2009) In Japan myocardial 
scintigraphy has been shown to reliably identify DLB even in mild cases.(Suzuki, et 
al., 2005) Earlier studies found reduced perfusion in occipital cortical areas in DLB as 
compared to AD on perfusion SPECT-images but this finding is not useful clinically 
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due to low sensitivity and specificity.(Lobotesis, et al., 2001) Promising findings have 
been reported also using quantitative EEG.(Bonanni, et al., 2008) In AD the 
concentration pattern of cerebrospinal fluid (CSF) proteins like beta-amyloid species 
such as a42, total tau and p-tau and the rate and degree of atrophy in hippocampal 
structures on MRI  have been established as a biomarker of the disease and included in 
the latest diagnostic research criteria.(Dubois, et al., 2007) However, the specificity 
against DLB is not high and thus CSF cannot presently be used to distinguish between 
AD and DLB.(Mollenhauer, et al., 2006) In DLB the concentration of S in CSF has 
not convincingly been shown to differentiate DLB from AD or normal 
controls,(Noguchi-Shinohara, et al., 2009; Spies, Melis, Sjogren, Rikkert, & Verbeek, 
2009) although the concentration of S oligomers in plasma have been suggested as a 
potential biomarker in DLB.(El-Agnaf, et al., 2006)  Low CSF concentrations of a42 
in PD have been found to correlate with poor cognition in cross-sectional studies, 
particularly regarding memory.(Alves, et al. 2010) Recently this finding was 
confirmed in a longitudinal study showing that low CSF levels of a42 predicted 
significant cognitive decline during the next two years.(Siderowf, et al. 2010) MRI 
was found to differentiate between DLB and AD and vascular cognitive impairment in 
a prospective study with pathological verification of the clinical diagnosis.(Burton, et 
al., 2009) To conclude, only DaTSCAN are readily available as a reliable clinical 
biomarker of DLB today. 
The clinical profile of DLB 
Cognitive profile 
In DLB most studies describe an initial impairment in visuospatial and executive 
cognitive domains as opposed to in AD where memory function and specifically 
encoding and storage of episodic memory is lost first. In a review from 2003 the 
authors concluded that DLB is a visual-perceptual and attentional-executive 
dementia.(Collerton, Burn, McKeith, & O'Brien, 2003)  
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Neuropsychiatric symptom profile 
Few studies have directly compared the neuropsychiatric symptom profile in DLB, AD 
and normal controls. Visual hallucinations are an intrinsic part of the DLB diagnosis 
and most authors agree that hallucinations, delusions including Capgras or 
misidentification syndrome, depression and anxiety are more frequent in DLB than in 
AD.(Ricci, et al., 2009) In PD impulse control disorders like pathological gambling, 
hyper-sexuality and compulsive buying have been described and found to be 
associated with dopamine-agonist treatment,(Weintraub, et al. 2010) but these 
symptoms have rarely been explored in DLB. Recently somatoform disorder, defined 
as medically unexplained symptoms, was found occurring in 7% of patients with PD 
and 12 % of DLB patients preceding the DLB diagnosis for 6 months to 10 years in all 
cases.(Onofrj, Bonanni, Manzoli, & Thomas 2010) Personality traits like diminished 
emotional response may distinguish DLB from AD.(Galvin, Malcom, Johnson, & 
Morris, 2007)
Sleep disturbances in dementia 
In DLB sleep and sleep disturbances have not been described in any detail, although 
RBD was recently included as a suggestive feature of the disease. Normal sleep 
changes as persons age and above 60 years of age normal persons sleep on average 6.5 
hours every night. Older people tend to fall asleep earlier and as a consequence also 
wake up early i.e. the so called phase advance.(Wolkove, Elkholy, Baltzan, & 
Palayew, 2007)  In addition old people have more sleep disturbances like insomnia and 
obstructive sleep apnea (OSA) and reduced amount of slow wave sleep and REM 
sleep.(Wolkove, et al., 2007)  
In DLB Farina et al. reported finding an overall 44.1% frequency of sleep 
disturbances,(Farina, et al., 2009) but the frequencies of specific sleep disturbances 
except RBD have not been reported. In one study DLB patients were found to have 
more overall sleep disturbances as compared to AD.(Grace, Walker, & McKeith, 
2000) 
In AD changes in sleep are more pronounced than in normal aging and differ 
substantially from normal control subjects at least in moderate and severe stages of the 
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disease. Sleep changes in AD are not diagnostically useful in mild forms of the 
disease.(Vitiello, Prinz, Williams, Frommlet, & Ries, 1990) Typical changes include 
phase advance, reduced amount of time asleep, disrupted sleep and reduced amount of 
slow wave sleep, altogether reducing sleep efficiency in these persons. Night time 
behaviours often induce excessive sleepiness during daytime. The frequency of sleep 
disturbances increase with dementia severity and are related to sundowning and 
agitation. Increased caregiver distress and early institutionalization and are reported to 
occur in 25-40% of patients with AD due to sleep disturbances.(Carpenter, Strauss, & 
Patterson, 1995; Dauvilliers, 2007)  
RBD with lack of relaxation of muscles during REM sleep phases and acting out of 
dream content has been reported to occur in about 10% of AD patients.(Sinforiani, et 
al., 2007) Other sleep disturbances like insomnia, restless legs syndrome (RLS), OSA, 
sleep related leg cramps (SRLC) and sleep walking (SW) have not been extensively 
studied in AD or other dementias. 
In PD, a wide range of different sleep disturbances have been described including 
insomnia, excessive daytime sleepiness (EDS), sleep attacks or unintended sleep 
episodes, REM sleep behaviour disorder (RBD), restless legs syndrome (RLS), sleep 
related leg cramps (SRLC), periodic leg movements during sleep (PLMS), obstructive 
sleep apnoea and sleep walking/ somnambulism.(Jauregui-Barrutia, Tijero-Merino, 
Gomez-Esteban, & Zarranz 2010; Mondragon-Rezola, Arratibel-Echarren, Ruiz-
Martinez, & Marti-Masso 2010)  
Sleep disturbances in dementia have been thought to relate to pathology in specific 
brain areas such as the suprachiasmatic nucleus, the hypothalamus and brainstem and 
pons area. Neurochemical changes including melatonin and acetylcholine and thus 
tend to differ in different types of dementia  related to the specific brain pathology of 
the type of dementia involved. 
In summary, specific sleep disturbances like RBD have been found to occur in the -
synucleinopathies, RBD may start several decades before cognitive and motor 
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symptoms,(Claassen, et al. 2010) but the frequency of RBD and other sleep 
disturbances have not been described in DLB. 
Motor symptoms in dementia 
In DLB the dementia syndrome develops within the first year of parkinsonian 
symptoms whereas in PDD dementia develops on the background of established PD. 
In DLB these symptoms do not typically start with unilateral tremor as in PD, but 
instead postural instability and gait disorder (PIGD) and rigidity.(Burn, et al., 2006) In 
VaD motor symptoms will depend on the specific location of vascular lesions and 
therefore parkinsonian symptoms in addition to paresis, paralysis and spasticity may 
occur.(Demirkiran, Bozdemir, & Sarica, 2001; Staekenborg, et al., 2008) Ballistic or 
chorea-like movements have also been described in relation to cerebral haemorrhages 
and infarctions.(Vidakovi , Dragasevi , & Kosti 1994) In pure AD motor symptoms 
will normally not occur initially but as the disorder progresses parkinsonian symptoms 
like gait disorder and rigidity will increase in later stages.(Wilson, et al., 2000). In 
heritable forms of FTD like frontotemporal dementia with parkinsonism linked to 
chromosome 17, parkinsonian motor symptoms are part of the clinical picture. 
Neuroleptic medication can cause or severely worsen parkinsonism and other motor 
disability in dementia, particularly in DLB and PDD.(Aarsland, et al., 2005)
Autonomic failure in dementia 
The  -synucleinopathies have been found not only to affect the CNS. Autonomic 
failure can be an early and prominent feature of the disease as a consequence of 
affection of the ganglia and peripheral nervous system and can be visualized with heart 
scintigraphy. Symptoms of autonomic failure are more common in DLB than in AD 
and include orthostatic hypotension, cardiac arrhythmias, syncope, constipation, 
impotence, urinary retention and excessive sweating.(Sonnesyn, et al., 2009) 
Pain in dementia 
Pain have not been studied in DLB, specifically not in mild dementia. In AD pain has 
been found to be frequent in advanced stages, and specific instruments have been 
designed to detect pain in dementia.(Husebo, 2009; Husebo, Strand, Moe-Nilssen, 
Husebo, & Ljunggren, 2009) 
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Mild cognitive impairment 
Recently a case series of MCI in DLB was presented; Of eight patients identified 6 
were male, 7 developed DLB and 1 continued to have MCI. 7 had RBD, 8 
parkinsonism, 6 fluctuations and 6 had visual hallucinations.(Molano, et al. 2010)  
Table 2 Clinical symptoms in mild DLB and AD
Symptom DLB AD 
Cognition Visuospatial and executive 
Fluctuating 
Memory 
Stable 
Neuropsychiatric Depression 
Delusions  
Hallucinations 
Depression 
Sleep REM sleep behaviour disorder 
Excessive daytime sleepiness 
Insomnia 
Motor Parkinsonism No motor symptoms in mild 
stages 
Autonomic Orthostatic hypotension No autonomic symptoms in 
mild stages 
Pharmacological treatment 
In DLB very few RCTs with cognitive enhancers exist although rivastigmine was 
studied and found to improve both cognition and psychotic symptoms.(I. McKeith, et 
al., 2000; I. G. McKeith, Wesnes, Perry, & Ferrara, 2004) Rivastigmine is therefore 
often preferred by the prescribing clinician if the patient can tolerate its side effects. 
Recent studies have suggested that memantine is a safe and a potentially effective 
treatment for DLB regarding both cognition and BPSD(Emre, et al., 2010; Aarsland, et 
al., 2009) 
AChEI’s are established as symptomatic treatment in mild AD and the same holds true 
for memantine in more advanced stages of the disease. Combinations of the two 
classes of anti-dementia drugs have been shown to be more effective in the 
symptomatic treatment of AD in some studies.(Farlow, Alva, Meng, & Olin, 2010) 
Levodopa has been shown to improve parkinsonian symptoms in DLB in open-label 
studies.(Molloy, McKeith, O'Brien, & Burn, 2005) There are no placebo-controlled 
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trials of antipsychotic drugs in DLB but several open-label reports suggest that 
atypical antipsychotics such as quetiapine and clozapine may be useful.(Kurlan, 
Cummings, Raman, & Thal, 2007; Poewe, 2005) However adverse effects are 
common and are sometimes severe including cerebrovascular incidents and increased 
mortality.(Sacchetti, Turrina, & Valsecchi, 2010) Autonomic failure can be treated 
symptomatically i.e. orthostatic hypotension can be improved by reducing anti-
hypertensive drugs and secure intake of sufficient amounts of liquids. Polyethylene 
glycol can be used to treat constipation, anticholinergic agents are used to treat bladder 
dysfunction but should be used with caution particularly in elderly patients who have 
cognitive decline. Phosphodiesterase inhibitors can be used to treat sexual 
dysfunction.(Zesiewicz, et al. 2010) RBD can be successfully treated using 
clonazepam, melatonin or pramipexole. RBD with concomitant synucleinopathy may 
be treated with AChEI.(Aurora, et al. 2010) Pharmacological treatment of DLB is 
however particular challenging as improving one aspect of the disease might worsen 
other aspects, for example will treating the motor symptoms with dopaminergic 
medication in some persons release or increase psychosis and delirium and symptoms 
of autonomic failure like orthostatic hypotension. Treating psychosis with 
antipsychotic medication will frequently increase parkinsonian motor symptoms and in 
many  patients result in severe worsening of both cognitive and motor symptoms and 
even sometimes lead to death, a syndrome termed “neuroleptic hypersensitivity 
syndrome.” Since there is a balance between cholinergic and dopaminergic activities 
treating cognitive impairment with AChEI’s may worsen motor symptoms and tremor.  
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Table 3 Pharmacological treatment in DLB 
Treatment 
target 
Prevalence* Screening Intervention Evidence 
Class I-IV** 
Impaired 
cognition 
100% MMSE 20-30 rivastigmine 
memantine 
donepezil 
galantamin 
I 
I 
IV 
IV 
Hallucinations/ 
delusions 
50%/ 40% NPI1 rivastigmine 
memantine 
donepezil 
galantamin  
clozapine 
quetiapine 
risperidon*** 
citalopram*** 
I 
I 
IV 
IV 
IV 
IV 
II 
II 
Depression 50% MADRS10 SSRI 
bupropion 
--- 
--- 
RBD 31% MSQ clonazepam 
melatonin 
pramipexole 
AChEI 
IV 
-- 
-- 
-- 
Insomnia 44% NPI melatonin -- 
EDS 41% MSQ/ ESS modafinil -- 
Parkinsonism 49% UPDRS levodopa IV 
* from the DemVest-study ** See Appendix for definition of evidence class I-IV. 
***not recommended 
   
Non-pharmacological treatment 
To our knowledge no systematic studies have yet been reported regarding the 
nonpharmacological treatment of DLB, but general principles regarding 
nonpharmacological interventions in dementia apply.  It is important to inform patients 
and caregivers regarding the characteristic features of DLB including the potentially 
harmful effects of RBD and neuroleptics. Most authors recommend identifying one or 
only a few target symptoms to deal with first. Online support groups for carers and 
information for carers, patients and professionals are available on the internet, see at 
http://lbda.org/ or http://www.lewybody.org/ 
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AIMS OF THE STUDY 
The primary objectives of this study were 1) to find the frequency of DLB in a referral 
sample of people with mild dementia, 2) to find the frequency and pattern of sleep 
disturbances in DLB and 3) to examine whether the core and suggestive symptoms of 
DLB cluster together in individual patients with mild dementia.  
The specific study aims were as follows 
1. To find the frequency of DLB in the DemVest-study applying the revised 
consensus criteria as compared to the original consensus criteria. (Paper 1) 
2. To find the frequency of DLB in different age groups and across different 
dementia severity groups. (Paper 1) 
3. To find the frequency of sleep disturbances in DLB and AD as compared to age 
matched control subjects. (Paper 2) 
4. Identify clinical significant correlates of sleep disturbances in mild dementia. 
(Paper 2) 
5. To explore whether the core and suggestive features of DLB cluster in persons 
with mild dementia. (Paper 3) 
6. To explore whether specific clusters based on the continuous measures of 
parkinsonism, visual hallucinations, cognitive fluctuations and RBD are associated 
with a specific pattern of cognitive failure in mild dementia. (Paper 3) 
7. To identify cut-off values on scales for  continuous measures of parkinsonism, 
hallucinations, cognitive fluctuations and RBD regarding the designation of what 
constitutes DLB. (Paper 3) 
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METHODS 
Design 
 The DemVest-study is a prospective study of dementia in Western Norway aiming at 
exploring various aspects of the dementia subtypes at baseline and on 12 months 
intervals thereafter. All 5 centres in old age psychiatry and geriatric medicine 
established at time of inclusion in Western Norway have participated in the inclusion 
and the 3 neurology departments agreed to refer all cases of suspected mild dementia 
to one of the study centres during the inclusion period.  Data for this PhD-thesis are 
based on the baseline examination in the DemVest-study. 
Inclusion criterion 
The inclusion criterion was any type of mild dementia. Mild was defined here as a 
MMSE score  20. Dementia should be diagnosed for the first time between 2005 and 
2007 in Rogaland and Hordaland counties. An age matched control group was 
recruited from the Mayo study of Aging, Mn. USA.(Roberts, et al., 2008) 
Exclusion criteria 
The exclusion criteria were; normal cognition, mild cognitive impairment, moderately 
and severe dementia with MMSE<20, schizophrenia or other functional psychosis, 
bipolar disorder, other organic dementia, severe medical illness or terminal diseases 
were causes for exclusion in the DemVest-study. 
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Dementia diagnosis 
The diagnosis of dementia was made according to the Diagnostic and Statistical 
Manual for Mental Disorders 4th edition. The diagnosis for Alzheimer’s disease 
dementia was made according to The National Institute of Neurological and 
Communicative Disorders and Stroke-Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA).(McKhann, et al., 1984) Vascular dementia (VaD)  
was diagnosed according to the National Institute of Neurological Diseases and 
Stroke-Association Internasjonale pour la Recherche et L’Enseignement en 
Neuroscience (NINDS-AIREN) criteria.(Roman, et al., 1993) DLB was diagnosed 
according to the revised consensus criteria.(I. G. McKeith, et al., 2005) A diagnosis of 
Parkinson’s disease dementia (PDD) was made according to the Task Force organized 
by the Movement Disorder study.(Emre, et al., 2007) Since clinical symptoms and 
brain changes are similar both Dementia with Lewy Bodies (DLB) and Parkinsons 
Disease Dementia (PDD) were grouped as Lewy-body dementia (LBD) in the sleep 
study. The clinician completed the Clinician Dementia Rating scale (CDR) range 0 – 
3. 0 meaning no cognitive impairment, 0.5 mild cognitive impairment or very mild 
dementia, 1 mild dementia, 2 moderately severe dementia and 3 severe 
dementia.(Morris, 1997) Activities of daily living were assessed using the Rapid 
Disability Rating Scale-2.(Linn & Linn, 1982) The clinical diagnosis was made by two 
of the researchers taking into account all available information and the diagnosis was 
revised annually. The research group including study nurses had several meetings 
before study start and also bi-annually after study start to ensure adequate reliability 
and consensus and harmonisation of the conduct of the study program. 
Clinical examination 
A detailed and comprehensive battery of assessment instruments was employed. We 
emphasized instruments that have been standardized and validated to diagnose people 
with early dementia including DLB. The history and clinical examination was 
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performed by the study clinician who was a psychiatrist experienced in old age 
psychiatry or a geriatrician. A trained study nurse performed a structured interview 
and tests of the caregiver and the cognitive battery with the participant with dementia. 
Neuropsychiatric assessment 
The psychiatric assessment focused on key symptoms such as visual hallucinations 
and depression and was based on the Neuropsychiatric Inventory (NPI). The NPI was 
specifically designed to assess psychiatric symptoms in subjects with dementia based 
on a structured interview of a caregiver. The NPI screens for 12 different 
neuropsychiatric symptoms; delusions, hallucinations, agitation, depression, anxiety, 
euphoria/mania, apathy, lack of normal conduct, irritability, aberrant motor behaviour, 
sleep and appetite/eating behaviour.  Each item is scored on a frequency scale 0-4 and 
on a severity scale 0-3 and a total score of frequency times severity 0-12 is calculated, 
i.e. with a total NPI score of 0-144. Included is a caregiver distress score 0-5 for each 
item with a total score 0-60.(Cummings, et al., 1994) A Norwegian version of the NPI 
have been validated, and was found to be reliable and valid in assessing 
neuropsychiatric symptoms in dementia.(Selbaek, Kirkevold, Sommer, & Engedal, 
2008) In addition patients and caregivers were asked whether visual hallucinations had 
ever occurred. The presence of recurrent and formed visual hallucinations was based 
on the NPI visual hallucinations item, the clinical interview and any comments in the 
medical record. Depression was rated using the Montgomery and Asberg Depression 
Rating Scale (MADRS) which is a clinical interview with 10 items scored 0-6 and a 
total scoring range 0-60. Depression was defined as a score above 10.(Montgomery & 
Asberg, 1979) A history of clinically relevant depression was asked for in the 
interview. Parkinsonism was rated using the UPDRS motor subscale which has a 
scoring range from 0 to 108. The score is given  based on an examination of the motor 
system performed by a trained physician.(Fahn, R.L., & Committee., 1987) A 
diagnosis of parkinsonism required two or more of the four cardinal symptoms: 
tremor, rigidity, bradykinesia and gait disturbance/postural instability. Marked 
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neuroleptic sensitivity required evidence of both motor and cognitive worsening after 
treatment with an antipsychotic agent.(Aarsland, et al., 2005) Fluctuating cognition
was rated using the Clinician Assessment of Cognitive Fluctuations(Walker, et al., 
2000) or the Mayo Fluctuation Questionnaire(Ferman, et al., 2004) using the 
recommended cut-off scores i.e. one example given from the last month from question 
a) or b) and a total score of 5 or more  from the Clinician Fluctuation Scale or 3 or 4 
features from the Mayo Fluctuation Questionnaire.(AASM, 2005)  
Neuropsychological examination  
A comprehensive battery of neuropsychological tests was administered by a trained 
study nurse to corroborate a history and/or clinical signs of cognitive impairment.
Validated and published norms were used.  
Verbal Memory 
The California Verbal Learning Test II (Delis, Kramer, Kaplan, & Ober, 1987) 
consists of a list of 16 words read 5 times and a distractor list, providing sub scores of 
immediate and delayed recall, free recall, recognition and discrimination.  
Language 
The Boston Naming Test is a highly sensitive tool to identify naming deficits and 
impaired word-retrieval capacities in a variety of neurodegenerative disorders. We 
used a 15-item version of the test.(Graves, Bezeau, Fogarty, & Blair, 2004) 
Visuospatial abilities 
Two subtests from the Visual Object and Space Perception Battery 
(VOSP)(Warrington & James, 1991) were used: the Cube and Silhouette tests. 
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Executive functions 
We assessed three different aspects of executive functioning: Verbal fluency 
(categorical) was tested by asking the patients to generate as many names of animals 
as possible within 1 minute.(B. A. Steinberg, Bieliauskas, Smith, Ivnik, & Malec, 
2005) The Trail Making Test A and B is as a measure of attention shift and 
psychomotor speed.(B. A. Steinberg, Bieliauskas, Smith, & Ivnik, 2005) The Stroop 
Color-Word Test is a test of selective attention, disinbition and interference.(Golden, 
1978) 
Sleep assessment 
Insomnia 
The Neuropsychiatric Inventory (NPI)(Cummings, et al., 1994) sleep item was used to 
diagnose and rate severity and frequency of insomnia. The score was based on the bed-
partners response to 4 items. The normal controls completed the NPI-Q(Kaufer, et al., 
2000) which is a simplified questionnaire. A composite score above 0 was defined as 
insomnia in accordance with the instructions for the scale.(Cummings, et al., 1994) 
Excessive daytime sleepiness  
The Epworth Sleepiness Scale(M. W. Johns, 1993) was administered to the caregivers 
for the persons with dementia and the normal control persons. This scale scores the 
likelihood of dozing in 8 different situations: while reading, while watching TV, while 
in the theatre or attending a meeting, as passenger in the car, during a rest and while 
talking to someone and after eating lunch. Each item is scored on a scale from 0 
meaning never falls asleep in this situation to 3 meaning high probability of falling 
asleep. The sum score is from 0 to 24 and a sum total score > 10 was defined as 
excessive daytime sleepiness.(M. Johns & Hocking, 1997) 
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The Mayo Sleep Questionnaire 
Parasomnias and sleep related movement and breathing disorders in dementia cases 
and normal controls were assessed using the Mayo Sleep Questionnaire (MSQ) which 
is a structured and validated instrument designed to screen for the presence of a wide 
range of sleep disturbances. The MSQ consists of a 16 items measure and is completed 
by a bedpartner who regularly sleeps with the subject 
(http://www.mayoclinic.org/sleep-disorders/research.html).  Originally both a patient 
version and a bedpartner version were used. The initial validation data involving 
patients (and their bedpartners) being evaluated in a Sleep Disorders Center(Boeve, 
Silber, Ferman, Smith, & Petersen, 2002) and a separate analysis involving patients 
(and their bedpartners) being evaluated in a Behavioral Neurology Clinic(Boeve, 
Ferman, Silber, & Smith, 2002) demonstrated the high sensitivity and moderate to 
high specificity for most items. (Boeve, personal communication) The sensitivity and 
specificity were superior for the bedpartner version and therefore only the bedpartner 
version has been used since 2002. New data from the normative group of elderly 
without dementia or other cognitive disorders are available.(Roberts, et al., 2008) 
Completion of this measure typically requires 5 minutes. 
Parasomnias 
REM sleep behaviour disorder is characterized by recurrent dream enactment 
behaviour during REM sleep.(Schenck, Bundlie, Patterson, & Mahowald, 1987) 
Probable REM sleep behaviour disorder was diagnosed if there was a history of 
recurrent, i.e. 3 times or more, nocturnal dream enactment behaviours recorded by the 
MSQ. REM sleep behaviour disorder was explored by means of questions to the bed 
partner regarding duration of symptoms, injuries to patient or bed partner, dream 
content and whether the dream content mirrored the movements of the patient during 
sleep.(AASM, 2005) Sleepwalking was assessed by means of a screening question to 
the bed partner: Did the patient ever go sleepwalking in the bedroom or house? 
Probable sleepwalking was diagnosed if this had happened 3 times or more. Sleep 
related leg cramps were explored by a screening question to the bed partner: Does the 
patient have cramps in the legs in the evening/night? Probable sleep  related leg 
cramps were noted if this had occurred on at least 3 occasions. 
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Sleep related movement disorders 
Probable periodic leg movements during sleep was diagnosed if the bed partner 
confirmed 3 or more episodes of recurrent periodic leg movements during sleep and 
not just while falling asleep. 
Restless legs symptoms was noted if the bed-partner could confirm that the patient 
complained about a restless, pins and needles or creepy-crawly sensation in the lower 
extremities on at least 3 occasions. (Allen, et al., 2003)  
Sleep related breathing disorder 
Obstructive sleep apnea was explored by means of a screening questions to the bed 
partner: Did the patient ever snore or did he get a feeling of suffocation while awake? 
Did the patient ever stop breathing while asleep? If yes: Does the patient get treatment 
for this condition like a continuous positive airway pressure machine? Probable 
obstructive sleep apnea was diagnosed if the bed partner reported that there had been 
at least 3 episodes of arrested respiration during sleep or answered “yes” to the 
question involving continuous positive airway pressure use since this indicates that 
patient had obstructive sleep apnea confirmed by polysomnography and is being 
treated as such.  
Diagnosing core and suggestive symptoms of DLB 
The hallucinations item from the Neuropsychiatric Inventory (NPI)(Cummings, et al., 
1994) was used for assessing hallucinations with a scoring range of 0 – 12. This score 
is rated by a caregiver and includes all types of hallucinations: visual, auditory, 
olfactory, tactile and gustatory. Normally a combined score (intensity X frequency) 
4 is regarded as clinical significant. The combined score of frequency times intensity 
for all modalities of hallucinations was used as a continuous measure for 
hallucinations, i.e. including both visual, auditive, tactile and gustatory hallucinations. 
Parkinsonism was identified using the UPDRS motor subscale with a scoring range of 
0-108 with no cut-off defined.(Fahn, et al., 1987) Fluctuating cognition was identified 
using the Clinician Assessment of Cognitive Fluctuations (n=120) scored 0-16, no cut-
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off defined.(Walker, et al., 2000) For a subgroup (n=39) the Mayo Fluctuation 
Questionnairewas applied, (Ferman, et al., 2004)  cut-off defined as 3. Scores from 
the Mayo Fluctuation Questionnaire  (0-4) were multiplied by 4 and thus it was 
possible to combine the two fluctuation scales. RBD was identified using the Mayo 
Sleep Questionnaire (MSQ).(Boeve, Ferman, et al., 2002)  A RBD score from 0-4 was 
calculated, no cut-off defined 1 point was given if the bed-partner reported dream 
enactment behaviour on 3 or more occasion An additional 1 point each was given if 
the patient was ever hurt, the bed-partner was ever hurt and if the patient told the bed-
partner about dreams where he or she was attacked and had to defend him/her selves 
and if the patient woke up and told about a dream and the details from the dream 
mirrored the patients movements during sleep. 
Biomarkers 
Imaging 
A structural MRI was performed in 185 cases. This was mainly to identify 
cerebrovascular disorder and other structural lesions. In a subgroup of 26 patients we 
acquired SPECT images of the striatum after injection of 123I-FP-CIT. 
Blood tests 
Electrolytes, haematological, liver, kidney and thyroid blood tests were performed to 
exclude organic causes of dementia and blood-cells and plasma were stored for future 
research. 
CSF 
In a subsample of participants a lumbar puncture was performed to exclude organic 
causes of dementia and CSF was stored for future analysis. CSF was not used for 
diagnosing AD at baseline. 
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Statistics 
We applied the software package SPSS version 15 for all analyses. A p-value of 0.05 
was considered statistically significant. Analyses in papers 1 and 2 consisted of rates 
and proportions using 95% confidence intervals.(CI) Between-group comparisons 
were made using one-way ANOVA for parametric variables with post-hoc 
comparisons using Scheffe tests and chi-square for categorical data. In paper 2 the 
proportion with sleep disorders was compared between groups using Fisher’s exact 
test and odds ratios with confidence intervals. Between-group comparisons of 
continuous data were made using the Mann-Whitney U test as the data were not 
normally distributed. For our third paper cognitive scores were calculated as 
standardized z-scores with zero as the mean value and 1 as the standard deviation for 
the 3 domains: Memory, Attention/Executive and Visuospatial. The memory cognitive 
z-scores were calculated from the CVLT-2 total score list 1-5, list A short delay and 
list A long delay. Attention/Executive cognitive z-scores were calculated from the 
serial 7s from the MMSE, Trail making test A and B and all items from the Stroop 
tests. Visuospatial cognitive z-scores were calculated from the Silhouette test only due 
to skewed data on the Cube test. 
The two-step cluster analysis procedure was used as a data driven approach for 
classifying patients in groups according to NPI hallucinations frequency times 
intensity score, parkinsonism as UPDRS-3 score, fluctuations score and RBD score. 
The two-step clustering procedure is based on a sequential pre-clustering procedure, 
followed by agglomerative hierarchical clustering method in a predetermined number 
of clusters.(Chiu, Fang, Chen, Wang, & Jeris, 2001; Zhang, Ramakrishnon, & Livny, 
1996) In order to determine the optimal number of clusters we chose the number of 
clusters that minimized Akaike’s information criterion. To test the robustness of the 
final cluster solution the sample was split in two random samples and re-clustered 
using the same number of clusters as in the whole-sample clustering procedure. Finally 
the agreement of the sub-sample clusters with the whole-sample cluster was 
calculated. Statistical significances between clusters for categorical variables were 
tested with Pearson’s Chi-square tests. Student’s t-tests were applied to test statistical 
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differences between normally distributed continuous data and Mann-Whitney U test 
for continuous nonparametric data.  Kruskal-Wallis tests were applied for one way 
analysis of variance of nonparametric data and one way analysis of variance for 
normally distributed data. Post hoc analyses applied Mann-Whitney U tests for 
continuous data and Pearson’s Chi-square tests for categorical data. 
Ethics and legal issues 
The DemVest-study is approved by the Regional Committee for Medical and Health 
Research Ethics in Western Norway and the Data Inspectorate of Norway. Financial 
support was received from the Regional Health Authorities of Western Norway, Helse-
Vest RHF and the Norwegian Research Council. The patients provided written consent 
to participate in the study after the study procedures had been explained in detail to the 
patient and a caregiver, usually the spouse or off-spring. Participants in the Mayo 
Clinic Study of Aging provided written consent; the full protocol as well as the sharing 
of data was approved by the Mayo Foundation Institutional Review Board. 
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RESULTS 
During the 2 year inclusion period we screened 657 subjects of whom 196 (29.8%) 
fulfilled the inclusion criteria (Fig 1, Tab 8). 461(70.2%) cases were excluded and 
reasons for exclusion were: 166 had moderately or severe dementia, 102 were not 
willing to participate, 79 had mild cognitive impairment, 48 had normal cognition, 24 
had depression and pseudo-dementia, 14 had newly diagnosed somatic or terminal 
disorder, 11 had bipolar disorder or psychosis, 7 had other neurological disorder, 4 had 
delirium and there were missing data in 6 cases. Of the excluded cases diagnosed with 
dementia(n=267), 91(34.0%) were diagnosed with AD, 22(8.2%) with DLB, 
27(10.1%) had VaD, 6(2.2%) had mixed dementia and 121(45.3%) had unspecified 
dementia. Thus, the frequencies of DLB and AD were lower and VaD was higher 
among the excluded compared to included subjects, and the diagnostic distribution 
differed significantly. Data from all 196 participants and their primary caregivers were 
analyzed in paper 1. In paper 2 participants with a sleep partner who completed the 
MSQ (n=151) were included and in paper 3 only persons with a complete dataset for 
the core and suggestive DLB symptoms (n=139) were included: 129 participants from 
baseline examination and an additional 10 who had a complete dataset at 12-months 
follow-up. 
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Figure 1 Flowchart of inclusions and exclusions in the DemVest-Study 
Total number of referrals 
screened 
n=657 
No dementia 
n=295 
Dementia DSM-IV 
n=362 
Exclusions 
MMSE19 
n=166
Inclusions  
MMSE20 
n=196
(Paper 1)
Sleep assessment 
MAYO 
N= 151  
(Paper 2)
Complete data for 
cluster analysis  
N=139 
 (Paper 3)
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Paper 1 
Frequency and case identification of Dementia with Lewy bodies using 
the revised consensus criteria 
Two of the authors independently reviewed all available information and kappa for a 
diagnosis of probable DLB versus non-DLB was 0.73. 
The frequency of DLB was 39/196 (20%) of whom 31 (16%) had probable and 8 (4%) 
possible DLB. The frequency of probable DLB increased by 25% as compared to the 
1996 criteria applying the revised 2005 criteria. The frequency of DLB did not differ 
significantly across dementia severity as measured with  mean CDR scores or age 
bands.  
Paper 2 
Frequency and Correlates of Caregiver Reported Sleep Disturbances in a 
Sample of Persons with Early Dementia 
We found a significantly higher frequency of sleep disturbances in LBD, i.e. both DLB 
and PDD combined, as compared to AD and normal controls. In LBD sleep 
disturbances were found in 89% compared to 64% in AD (p=0.008). The most striking 
difference was the much higher proportion with probable REM sleep behaviour 
disorder and excessive daytime sleepiness in LBD compared to the other groups 
Having any sleep disturbance in mild dementia correlated with both anxiety (p=0.025) 
and depression.(p=0.029) 
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Paper 3  
Core and suggestive symptoms of Dementia with Lewy Bodies cluster in 
persons with mild dementia 
Finally in the third paper we found that the core features of DLB (visual 
hallucinations, parkinsonism and cognitive fluctuations) and the suggestive feature 
RBD clustered in our participants with mild dementia. The analysis identified four 
clusters and the agreement of the sub-sample clusters with the whole-sample cluster 
was 91% (127/139). In cluster 1 (n=21, ) participants had high scores for 
hallucinations, parkinsonism and fluctuations and an intermediate score for RBD and 
we labelled this cluster the Lewy Body Dementia (LBD) cluster. In cluster 2 (n=17, 
xx%) participants had intermediate scores for hallucinations, parkinsonism and 
fluctuations but a high score for RBD and this cluster is labelled the RBD cluster. In 
cluster 3 (n= 81, xx%) participants had low or zero scores for all DLB symptoms and 
this cluster was labelled the non-LBD cluster. Finally in cluster 4 (n=20, xx%) 
participants had high fluctuation scores and low scores for hallucinations, 
parkinsonism and RBD and consequently this cluster was labelled the Cognitive 
Fluctuation (CF) cluster. Participants in the LBD-cluster had significantly more 
impaired viseospatiale abilities (p=0.002) as compared to the other clusters. Cut-off 
values for the core features and RBD were suggested.  
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DISCUSSION 
Findings in context 
Here we take the opportunity to discuss issues that have not been previously discussed 
in the three published papers, to present and discuss data reanalyzed for this thesis and 
to discuss our findings compared to the most recent data published, i.e. data published 
after the 3 papers were submitted. 
Our main findings in this thesis were that 1) 20% of the participants in the DemVest-
cohort fulfilled the revised clinical criteria for DLB. 2) 71% of the dementia 
participants had caregiver reported sleep disturbances as compared to 56% of the 
normal controls, and the caregivers reported more sleep disturbances among the LBD 
patients as compared to AD patients. Finally, 3) we found that the DLB symptoms 
cluster in individuals with mild dementia, providing empirical support for the 
diagnosis DLB.  
The frequency of DLB 
196 participants fulfilled DSM-IV diagnostic criteria for dementia and all these were 
then evaluated according to the core features of DLB, i.e. visual hallucinations, motor 
parkinsonism, fluctuations in cognition and consciousness and RBD. 31 participants 
(15.8%) were given a diagnosis of probable DLB. They had 2 core features or 1 of the 
core features plus RBD. 8 participants (4.1%) were given a diagnosis of possible DLB 
because they had one core feature of DLB without fulfilling diagnostic probable 
criteria for any other subtype of dementia. 
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Table 4 Number of participants fulfilling the two sets of diagnostic criteria  
Diagnosis Probable DLB Possible DLB 
Criteria 1996 2005 1996 2005 
Number 25 31 13 8 
Visual hallucinations 24 25 3 2 
Parkinsonism 11 14 8 5 
Fluctuations 17 18 3 2 
RBD  10  0 
123I-FP-CIT SPECT  3   0 
Neuroleptic sensitivity  0  0 
Some of the participants diagnosed with a non-DLB dementia also fulfilled criteria for 
possible DLB, i.e. they had one core feature or RBD, but as we choose to put only one 
diagnosis for each participant, these data have not been analyzed and are not included 
in this thesis. In the revised consensus criteria severe neuroleptic sensitivity and a 
positive CIT-SPECT/ DaTSCAN are included as suggestive features of DLB. In our 
cohort no participants reported severe neuroleptic sensitivity and overall only 13 
(6.6%) participants were treated with neuroleptics at baseline. Unfortunately, it was 
not possible to examine all the included participants with a DaTSCAN, and thus only 
26 scans were performed at baseline. 3 participants were given a diagnosis of probable 
DLB based on having one core feature and a positive DaTSCAN.    
To our knowledge no previous studies had reported on the frequency of DLB 
according to the revised clinical criteria at time of publication. Recently an Italian 
group reported findings from Italian memory clinics originally applying the 1996 
criteria, reanalyzing their data according to the revised criteria. They reported an 
increase in the proportion with probable DLB from 78/102 to 82/102, an increase of 
about 4 % as compared to 25 % in our study. The Italian study applied both 
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retrospective and prospective cases and did not report on how sleep disturbances like 
RBD was screened for and diagnosed.(Farina, et al., 2009)  
Our findings are comparable to epidemiological studies applying stringent 
methodology to detect DLB according to the original criteria,(Rahkonen, et al., 2003; 
Stevens, et al., 2002) although many studies have reported much lower 
frequencies.(Zaccai, et al., 2005) Nevertheless, our findings are probably still an 
underestimation of the true frequency of all cases fulfilling the revised clinical DLB 
criteria because 1) all participants were only given one diagnosis. If the non-DLB 
cases had been given a secondary dementia diagnosis, many cases would fulfil the 
possible DLB criteria in addition to the AD criteria. A substantial proportion of those 
diagnosed as having possible DLB fulfil criteria for probable DLB after one 
year.(O'Brien, et al., 2009) 2)Applying a DaTSCAN in all participants would probably 
have yielded more participants with a probable or possible DLB diagnosis. 3)Finally, 
we did not have access to cardiac scintigraphy, which has demonstrated high 
sensitivity for diagnosing DLB.(Yoshita, et al., 2006)    
In a study with autopsy verified diagnosis it was shown that in persons with mild DLB 
only few of them expressed the core features. As a consequence one might expect that 
many of our cases diagnosed as non-DLB will eventually develop into a more typical 
phenotype during follow-up,(Tiraboschi, et al., 2006)  at least among the cases with 
one core or suggestive feature diagnosed with another subtype of dementia. A 12 
months follow-up study of persons with possible DLB applying CIT-SPECT 
/DaTSCAN found a positive scan at baseline to have high predictive power for a 
clinical probable DLB diagnosis at 12 months follow-up and a negative scan to have a 
high predictive power for diagnosing AD at 12 months.(O'Brien, et al., 2009)
The lower than expected prevalence and incidence of DLB in previous studies might 
reflect the fact that DLB is not readily detected on memory based screening 
instruments alone. It is known that cognitive fluctuations are hard to detect reliably 
without specific screening instruments.(Mega, et al., 1996) Visual hallucinations 
occurring in individuals without memory problems may not always be considered as 
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part of a dementia diagnosis clinically. In persons presenting with motor parkinsonian 
symptoms a detailed cognitive and ADL screening are not always performed. In 
addition sleep disturbances in dementia is normally not included in the clinical 
interview and examination and therefore new screening instruments to detect the 
specific features of DLB need to be developed to more reliably detect this condition.  
The prevalence and incidence of DLB is still not known in different populations. 
Therefore more rigorously designed studies are needed to establish the prevalence and 
incidence of DLB in different geographical areas, age groups and populations. 
Screening-instruments for DLB should include neuropsychological tests for attention, 
visuospatial function and executive function and not rely exclusively on memory 
based tests. A structured interview for the carer should be added to the diagnostic 
evaluation. Standardized scales to measure parkinsonism, hallucinations, fluctuating 
cognition and consciousness, neuroleptic sensitivity and REM sleep behaviour 
disorder should be included according to recommendations in the last consensus 
paper.(I. G. McKeith, et al., 2005) In addition cut-off points on clinical rating scales 
are needed as only one study for fluctuations have reported this.(Ferman, et al., 2004) 
The proportion of DLB across age bands 
The proportion of persons with DLB did not differ significantly across the three age 
bands; <70 years, 70-80 years and  >80 years. A trend was shown, the proportion of 
persons with DLB being higher in the >80 years group, i.e. the oldest age group. 
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Figure 2. Baseline diagnoses in 3 age bands 
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A systematic review of prevalence and incidence studies in DLB showed that different 
age groups were included, i.e. >65 years and >75 years, in different studies.(Zaccai, et 
al., 2005) The Finnish study by Rahkonen et al. found the DLB frequency in their 
dementia cohort in the 75+ group to be 22%, and the UK study from London found the 
frequency of DLB in the 65+ group to be 31%. Unfortunately, the studies referred in 
this review have applied different methodology and different adaptations of the 
diagnostic criteria, making direct comparison between studies of different age groups 
in different studies difficult. However, the best methodologically studies in this review 
found a higher proportion in the 65+ group(Stevens, et al., 2002) than in the 75+ 
group(Rahkonen, et al., 2003) when including persons with both probable and possible 
DLB, opposite the trend in our study. In Stevens et al. visual hallucinations were 
mandatory for a DLB diagnosis and as such a specific adaptation to the 1996 criteria 
were introduced in this study. Diagnosis relied both on a clinical examination and case 
records and specific instruments to detect the core and suggestive features of DLB 
were not applied. Their screening instrument, the Short-CARE, might not have 
detected mild cases as only individuals who needed assistance were detected. In the 
Finnish study by Rahkonen et al. the proportion with DLB and other dementias was 
reported in 5 years intervals from 75 to 90+. The highest proportion of DLB (50%) 
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were found in the 80-84 years age group, comparable to our findings. In the Hisayama 
Study,(Matsui, et al., 2009) a study of incident dementia with pathological diagnostic 
verification, Matsui et al. found a low incidence of DLB across the age bands from 65 
years to 85+, as opposed to AD where they found increasing incidence with age. VaD 
was found to be the second most common form of dementia as known from other 
Asian  dementia studies, with higher frequencies of VaD and lower DLB frequencies. 
Our study was not powered to explore the proportion of DLB as compared to other 
dementias in the different age groups. Finding the true frequency of DLB in the 
different age bands in different communities would inform clinicians on where to look 
for the diagnosis and researchers on possible risk factors and provide insight into the 
complex relationship between age-related changes and disease-related pathologies.  
Proportion of DLB across severity groups 
Dementia severity was measured by the Clinical Dementia Rating scale (CDR) which 
is  composed of the subitems: memory, orientation, judgement and problem solving, 
community affairs, home and hobbies and personal care. The proportion of persons 
with DLB did not differ significantly in two severity groups based on mean total CDR 
score (5.2); CDR 0.5-5 and CDR >5. 
Figure 3. Baseline diagnoses in two severity groups based on mean CDR-scores
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For this thesis we recalculated the CDR scores with an online algorithm from the 
following web site: http://www.biostat.wustl.edu/~adrc/cdrpgm/index.html giving new 
sum scores for each participant; 0 (no cognitive impairment), 0.5 (Mild cognitive 
impairment), 1 (mild dementia), 2 (moderately severe dementia) or 3 (severe 
dementia). These previously unpublished data are presented below in table 5. The 
proportion of DLB patients did not differ significantly across these new CDR severity 
groups. Of note, some patients had CDR=2, i.e. moderate dementia, despite the 
inclusion of only mild dementia and more importantly a large proportion scored 0.5 on 
the CDR scoring signifying MCI, but all were fulfilling the criteria for dementia and 
had impairment in their ADL-functioning due to impaired cognition. This is due to the 
inclusion criterion being based on MMSE score of 20 or higher, rather than the 
composite score being the basis for CDR scoring. 
Table 5 New CDR scores  
CDR 0.5 1.0 2.0 p-value 
AD (%) 40.9 53.5 5.5 0.254 
DLB (%) 39.4 45.5 15.2 0.144 
P-values based on Pearson chi-square test 
In the Finnish study Rahkonen et al. included all stages of dementia in the community 
making comparison to our data difficult. They concluded that their DLB patients were 
at a less severe stage and had a shorter duration of symptoms as compared to other 
types of dementia. This might reflect the fact that diagnosing DLB in severe dementia 
is difficult due to the fact that in advanced dementia the phenotype is rather similar 
independent of the initial type of dementia. These findings contrasts the findings from 
our study where we only included cases with mild dementia referred to an out-patients 
clinic based on a MMSE score of 20 or above.  To conclude, we still do not know if 
the frequency of DLB is different in different dementia severity groups and further 
studies specifically designed to address this question are welcome. 
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Figure 4 The proportion with different severity stages of DLB in two studies  
Comparing the two sets of clinical diagnostic criteria 
In the revised clinical diagnostic criteria for DLB from 2005 a set of features are 
included as “suggestive features” to increase sensitivity: RBD, severe neuroleptic 
sensitivity and a CIT-SPECT/DaTSCAN or PET imaging demonstrating reduced 
uptake of  dopamine transporter. In our study neuroleptic sensitivity was not reported. 
All the included participants were screened for RBD with the MSQ but only a small 
proportion underwent a DaTSCAN. The core features and RBD were rated 
independently by two of the authors yielding a Cohen’s kappa, a statistical measure of 
inter-rater agreement for categorical data, of 0.73, i.e. substantial agreement. Probable 
and possible DLB was diagnosed according to the revised and original criteria and the 
two results were compared. One limitation is that the two sets of criteria were not 
applied independently and blinded to the opposite criteria by the two raters. More 
cases fulfilled criteria for probable DLB with the revised criteria because RBD (n=4) 
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and  CIT-SPECT (n=2) made these convert from possible to probable DLB, i.e. the 
revised criteria were more sensitive for the clinical diagnosis of probable DLB. 
Gender 
In the -synucleinopaties a male predominance has been reported in several cohorts 
including DLB, although this has not always been confirmed in community-based 
studies. In PD a male predominance is established.(Alves, et al., 2009) In the Finnish 
community based study from Kuopio only 13% of the DLB patients were 
male.(Rahkonen, et al., 2003) Others have found an equal sex distribution(Farina, et 
al., 2009) and in a systematic review of prevalence and incidence studies of DLB no 
relation to sex was found.(Zaccai, et al., 2005) In our study the proportion of males 
was significantly higher in DLB (49%) as compared to AD (30%) 2 =5.060,  p=0.024. 
Our finding is comparable to case reports reporting a male predominance in DLB and 
this is known also in other -synucleinopaties like PD, MSA and RBD.(Alves, et al., 
2009; Boeve, et al., 2003)  To establish if a male predominance holds true in DLB a 
larger community-based study with appropriate design will be needed. 
The frequency of sleep disturbances and clinical correlates 
In paper 2 we reported on the frequency of caregiver reported sleep disturbances in 
mild dementia and normal controls. Clinical correlates of sleep disturbances were 
explored in the dementia cohort. Only those participants who had a sleep-partner at the 
baseline examination were included in the analysis for the second paper. The control 
group was comprised of participants in the Mayo Clinic Study of Aging(Roberts, et al., 
2008) who are largely of northern European heritage. They are randomly selected 
community dwelling residents of Olmsted County, Minnesota, who do not carry a 
diagnosis of dementia. They completed the same sleep assessments as the patients in 
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Norway. The Kokmen Short Test of Mental Status (STMS)(Kokmen, Naessens, & 
Offord, 1987; Tang-Wai, et al., 2003) (range 0-38 and cut-off point for dementia 
29/38) was used as the mental status examination in the Mayo Clinic Study of Aging 
rather than the MMSE.  MMSE scores were calculated from the STMS scores based 
on a nomogram involving several thousand subjects (unpublished data, Department of 
Neurology, Mayo Clinic, Rochester, Minnesota, USA).  
The LBD group comprised 29 persons with mild DLB and 10 persons with mild PDD 
and thus the power to detect differences in the frequency of sleep disturbances 
between the dementia subtypes, i.e. between LBD and AD, was increased. For this 
thesis we have chosen to present the additional sleep-data concerning DLB and PDD 
separately as well, see table 6 & 7 below. The frequency of insomnia in DLB as 
compared to AD was no longer statistically significant, probably reflecting  that our 
study was not adequately powered to find such a difference. Statistics have now been 
included for the frequency of somnambulism, and although the numbers are small, 
there are significant differences between diagnostic groups. 
Table 6 Characteristics of the study groups 
LBD  DLB PDD AD p-
value1 
N (%) 39* (26.5) 29 (19.2) 10 (6.6) 97  (63.6)  
Age 78.0 (7.7) 79.0 (7.9) 75.2 (6.7) 74.5 (7.3) 0.009 
Male 25(64.1) 16 (55.2) 9 (90) 33 (35.1) 0.082 
Education 9.1 (2.7) 9.2 (2.7) 8.9 (3.1) 9.6 (3.1) 0.518 
Duration of symptoms 3.1 (2.2) 3.5 (2.2) 2.1 (1.7) 2.3 (1.5) 0.003 
MMSE 23.9 (2.7) 23.4 (2.7) 25.5 (1.9) 23.9 (2.3) 0.292 
CDR 0.93 (0.51) 0.98 (0.56) 0.75(0.27) 0.86(0.36) 0.659 
Total NPI severity (SD) 8.41 (5.52) 9.4 (5.3) 5.5 (5.4) 6.44(5.25) 0.008 
Hypnotics 4 (10.0) 3 (10.3) 1 (10) 6 (6.3) 0.695 
AChEI 9 (22.5) 8 (27.6) 1 (10) 44 (45.8) 0.088 
Memantine 2 (5.0) 2 (6.9) 0 1 (1.1) 0.134 
Numbers represent number of subjects (%) or mean score and standard deviation.*29 
DLB cases and 10 PDD cases. Differences between groups were analyzed with 
Fisher’s exact tests for categorical data and Mann-Whitney tests for continuous data.  
1AD vs. DLB. 
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Table 7 Frequency of sleep disturbances in patients with mild dementia 
  LBD DLB PDD  AD 1p-value 
N (%) 39 (25.8) 29 (19.2) 10  (6.6) 97  (64.2)  
Any* 31 (88.6) 23 (79.3) 8     (80) 55  (56.7) 0.031 
pRBD 15 (38.5) 9   (31.0) 6     (60) 9      (9.3) 0.006 
pPLMS 7   (21.2) 6   (23.1) 1  (14.3) 8      (8.9) 0.081 
pRLS 12 (30.8) 8   (27.6) 4     (40) 13  (13.4) 0.069 
EDS 13 (40.6) 10 (41.7) 3  (37.5) 15  (16.7) 0.013 
Insomnia 17 (47.2) 12 (44.4) 5  (55.6) 23  (24.0) 0.053 
pSRLC 14 (42.4) 11 (42.3) 3  (42.9) 17  (18.7) 0.019 
pOSA 9   (25.7) 9   (34.6) 1     (10) 13  (14.9) 0.045 
SW 6   (15.4) 4   (14.3) 2     (25) 1      (1.1) 0.010 
* Any sleep disturbance. Numbers represent number of subjects (%). Differences 
between groups were analyzed with Fisher’s exact tests. 1AD vs. DLB. 
We found a higher frequency of all sleep disturbances in the mild dementia cohort 
(71%) as compared to the normal controls (56%) applying the NPI and the MSQ. The 
NPI reports the frequency of aberrant night time behaviour, included difficulties 
falling asleep or staying asleep, during the last four weeks and the MSQ reports the 
frequency of sleep disturbances that have occurred on at least 3 occasions, i.e. during 
an indefinite time frame, and thus the frequency of insomnia is registered within  a 
much shorter time frame as compared to other sleep disturbances reported here. The 
frequency of sleep disturbances applying the NPI sleep item has been previously 
reported in dementia and normal controls, but unfortunately neither the Cache County 
Study(M. Steinberg, et al., 2006) nor the Nakayama Study,(Ikeda, et al., 2004) both 
community based dementia studies applying the NPI, reported the frequency of 
aberrant sleep behaviour. In the Cardiovascular Health Study, a large US population 
based dementia study, Lyketsos et al. reported finding significantly higher frequency 
of sleep disturbances applying the NPI in participants with dementia (27.4 %) as 
compared to their MCI group (13.8 %) p<0.001. Unfortunately, they did not report the 
frequency of sleep disturbances from the general population.(Lyketsos, et al., 2002) 
Recently, findings from a UK community based neuropathology dementia cohort, the 
MRC CFAS study, was reported. Surprisingly, the authors found the same frequency 
of sleep disturbances in their normal controls (43.8 %)  as in the dementia participants 
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( 42.0 %). Both the dementia participants and their caregivers were asked about 
“difficulty getting or staying asleep at night or problems falling asleep during the day, 
”(Savva, et al., 2009) which reflect the rather wide definition of sleep problems in this 
study not asking for specific sleep disorders or applying the NPI sleep item. To our 
knowledge data from the MAYO sleep questionnaire has not yet been published from 
any other dementia cohort.  
The frequency of having any sleep disturbances in mild LBD was higher ( 89%) than 
in mild AD (64%) and in normal controls. (56%) Previously the frequency of sleep 
disturbances in DLB has not been extensively studied. Data not available to us at the 
time of publication were recently reported from Italian memory clinics.(Farina, et al., 
2009) In their cohort of DLB patients, comprising only 4.8 % of the dementia patients, 
sleep problems were reported in 44.1 % as compared to 79 % in our cohort. 25.5 % 
had insomnia, about half the frequency in our study with 44 % in DLB, 12.7 % had 
RBD as compared to 31 % in our study and hypersomnia in the daytime was reported 
in 10.8 % as compared to 42 % with EDS in our study. Direct comparison between the 
studies is difficult as the Italian study applied the 1996 criteria and reported 48 % use 
of neuroleptics as compared to only 13 % in our study. Importantly, they did not report 
how sleep problems were screened for or diagnosed. 
We found that depression and anxiety correlated with sleep disturbances in mild 
dementia thus demonstrating the clinical significance of sleep disturbances in 
dementia. To our knowledge this has not previously been reported.  
Four clusters revealed in mild dementia 
The results are based on a proportion of the participants from paper1(n=129) plus an 
additional 10 at 12 months follow up. To be included in these analysis participants 
needed a complete dataset for the NPI hallucinations item, a complete UPDRS-3 score, 
a fluctuation score and a RBD score. Using objective, rater-independent statistical 
procedures, thereby avoiding the risk for circularity inherent in a purely clinical 
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diagnostic approach, we identified 4 clusters in our mild dementia cohort based on 
scorings on continuous scales for hallucinations, fluctuations, motor parkinsonism and 
RBD. The NPI hallucination item was applied, including hallucinations for all 
modalities. For this thesis we reviewed the first 13 participants reporting scoring 1 or 
more on the NPI hallucinations item: 12 of 13 (92%) reported visual hallucinations 
and 5 of these in addition reported auditory hallucinations. 1 of 13 reported auditory 
and gustatory hallucinations only. The fluctuation score was composed of two 
different scales; 120 participants completed the Clinician Assessment of Cognitive 
Fluctuations and a subgroup of 39 completed the Mayo Fluctuation Questionnaire. The 
two scales were combined to one common fluctuation score by multiplying the Mayo 
score by 4 yielding a 0-16 total fluctuation score for all participants. The concordance 
between the two scales have not been examined and they may thus measure different 
aspect of cognitive fluctuations. 
The RBD score was based on the four questions regarding RBD from the MSQ but 
only a small proportion of the participants scored more than 1 point here. Thus some 
other scoring of RBD like the RBDQ-HK(Li, et al. 2010) a 13 item scale scored 0-100 
would be more appropriate for future research. This scale probably would have to be 
made available in a caregiver/ bed-partner version to be appropriate in dementia 
research.  
Different cognitive profiles in clusters 
Standardized Z scores for the three cognitive domains memory, attention/executive 
and viseospatial were calculated.  We found the Z-score for the visuospatial cognitive 
factor in the LBD cluster to be significantly more impaired as compared to the non-
LBD cluster.(-0.36 vs. 0.14, p=0.002) Memory was more impaired in the non-LBD 
cluster, although not significant. These findings are in accordance with previous 
findings comparing cognitive profiles in DLB and AD.(Collerton, et al., 2003) 
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Table 8 Cognitive z- scores in clusters 
Cluster1 
LBD 
Cluster2 
RBD 
Cluster3 
Non-LBD 
Cluster4 
CF 
p-value 
Memory 0.26(1.32) 0.12(1.30) -0.11(0.9) 0.12(1.1) 0.664 
Viseospatial -0.32(0.62) 0.06(0.80) 0.14(0.69) -0.02(0.85) 0.029* 
AttExecutive -0.10(0.39) 0.15(0.60) -0.03(0.51) -0.06(0.55) 0.717 
Scores are mean and SD Z-scores.  Overall p-values are calculated from Kruskal-
Wallis test, post hoc tests Mann Whitney U tests. *Cluster 1 vs. cluster 2 significant at 
p=0.07 Cluster 1 vs. cluster 3 significant at p=0.002 Cluster 1 vs. cluster 4 significant 
at p=0.106 
Thresholds for core and suggestive features of DLB 
Based on median scores for the core symptom of DLB and RBD scales we proposed 
cut-off values on these scales to designate what is sufficient for a DLB diagnosis. 
Scoring 1 or more on the NPI hallucinations item, fluctuation score and RBD sore or 
10 or more on the UPDRS-3 scale can be used as a clinical guide to identify the LBD 
cluster according to our findings. These findings need to be confirmed by others and 
confirmation of the validity of clusters awaits a biomarker or pathology study. 
The definition of cognitive fluctuations 
Cognitive fluctuations are not strictly defined regarding content, duration or intensity.  
The revised DLB criteria recommends using some kind of formal assessment of 
fluctuations. The One Day Fluctuation Assessment Scale, The Clinician Assessment of 
Fluctuation and the Mayo Fluctuations Composite Scale are all mentioned as possible 
tools. It is recommended that the rater has adequate training in applying the scales that 
are used.(I. G. McKeith, et al., 2005) In our study we applied two different scales, i.e. 
the Clinicians Assessment of Fluctuations and the MAYO scale both defining different 
aspects of cognitive fluctuations. The two scales have not been directly compared in 
the same set of patients and therefore we cannot claim that they actually measure the 
same phenomena of cognitive fluctuation.  
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Methodological issues 
Cross sectional design 
All three papers are based on data collected cross-sectionally, i.e. at one time point, 
and thus no conclusions regarding causality can be drawn based on our findings. We 
used data from the baseline examination in the DemVest-study, a prospective dementia 
study specifically designed to explore all aspects of Dementia with Lewy Bodies 
during the time span of the disease. The core and suggestive features of DLB are 
measured at the time of inclusion and participants might therefore fulfil other 
diagnostic criteria at a different time of examination. To our knowledge, the 
consistency of these features over time has not been explored. The same features are 
used as basis for the cluster analysis in paper 3 and the different sleep disturbances are 
also screened for at the baseline examination and might change over time.  
Case selection, recruitment and potential bias 
We estimated that the screened subjects represent about 5 % of incident cases in our 
catchment area during the inclusion period. This is based on the 14% elderly in the 
counties of Rogaland and Hordaland with a total population of 900000 and an 
expected incidence of dementia in this group of 1 new cases per 55 
elderly/year.(Andersen, et al., 1999)  As we screened all referrals to all out patients 
clinics in a defined area during a two year period we wanted to secure inclusion of a 
proportion of cases with mild dementia as unselected as possible, although we 
acknowledge that the proportion of referrals is low as compared to the frequency of 
new cases in our catchment area during the two year period. The DSM-IV criteria for 
diagnosing dementia are the most sensitive diagnostic criteria for diagnosing 
dementia,(Wancata, Borjesson-Hanson, Ostling, Sjogren, & Skoog, 2007) and thus 
probably few cases are lost applying using these criteria. On the other hand these 
criteria may be less specific as compared to the ICD-10 criteria. Regarding both AD 
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and VaD we applied the research diagnostic criteria including cases fulfilling both 
probable and possible criteria. These criteria are the most specific and least sensitive. 
Regarding vascular dementia the prevalence is known to vary widely depending on the 
specific set of criteria applied. The NINDS-AIREN criteria that we applied have been 
found to be the least sensitive of the criteria for VaD and suggestions to update them 
have been put forward.(Gold, et al., 2002)  
Unfortunately, we did not record how many of the included cases were referred from 
neurology to one of the participating centres, but based on our clinical impression the 
neurology departments evaluate rather few cases with preferably younger patients. 
Thus, we believe that only a small proportion of all included was referred from the 
neurology departments. Among the included subjects, 53% were included by old age 
psychiatry and 47% by geriatric medicine clinics. The proportion with DLB was 27.9 
% in the cases from Old Age Psychiatry out-patients clinics and 10.9 % from Geriatric 
Medicine. In Norway it has been shown that the referred cases are younger, but 
otherwise similar, to the cases with dementia not referred to out-patient 
clinics.(Gausdal & Gjøra, 2007) One might speculate that DLB cases would be 
referred more often due to higher frequencies of BPSD. A community based survey 
screening random inhabitants  in a defined area found an even higher frequency of 
DLB as compared to our study when including both probable and possible 
DLB.(Rahkonen, et al., 2003) This is probably partly due to methodological 
differences, but the possibility that the prevalence of DLB differs in different 
populations cannot be ruled out. 
Methods of measurement 
The NPI was not specifically designed to detect insomnia in mild dementia, and the 
definition of insomnia includes reduced function during the daytime in addition to the 
problems getting to or staying asleep. The normal controls answered the NPI-Q, a 
shorter version which might not detect the same individuals as the full version of the 
NPI. Although in PD it was reported that clinical interview alone with the patient and 
bed-partner only detected about half of the cases with RBD,(Gagnon, et al., 2002) the 
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MSQ has been found to have acceptable sensitivity and specificity to detect the 
different sleep disturbances. (B. Boeve, personal communication 2009) To formally 
diagnose conditions like RBD and PLMS a Polysomnography (PSG) must be included 
in the examination. Different screening measures were applied in dementia and normal 
controls, i.e. MMSE and Kokmen. The MMSE cut-off for mild dementia might lead to 
relatively more DLB cases being included since the MMSE is less sensitive for this 
group, and thus moderately demented patients with DLB might be included in our 
cohort. 
Confounding factors 
Only univariate analyses are applied in these three cross-sectional studies.  These are 
known to be subject to a range of possible biases. As an example we did not control 
for sex, age, education, the different drugs taken by the participants in the three 
studies, and one might speculate that AChEI would reduce the frequency of core 
symptoms, sleep disturbances, caregiver distress and disturb the clusterization of the 
participants. However, there were not major differences between the DLB and AD 
groups. Still, applying multiple regression analyses controlling for potential biases 
might have yielded slightly different results. 
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Conclusions, implications and directions for future 
research 
Conclusions  
In geriatric medicine and old age psychiatry combined 20% of persons with mild 
dementia were diagnosed to have DLB. This made DLB the second most frequent 
primary dementia disorder in our cohort. We found 80% of the DLB patients to have a 
sleep disturbance, significantly more than in the AD group and in normal age-matched 
controls. In DLB, the frequencies of REM sleep behaviour disorder, excessive daytime 
sleepiness and sleep walking differed from AD. Anxiety and depression were found to 
be clinical correlates of sleep disturbances in our mild dementia cohort. Finally, in the 
cluster analysis we identified four clusters: in cluster 1, named the LBD-cluster, 
participants with a clinical diagnosis of DLB and PDD clustered together based on 
their scores on scales for hallucinations, fluctuations, motor parkinsonism and RBD, 
thus providing empirical support for the DLB diagnosis. We provided cut-off scores 
on scales for the core and suggestive symptoms in DLB and identified a distinct 
cognitive profile in the LBD- cluster. 
Implications for clinical practice 
DLB is common in out-patient dementia clinics in Western Norway and is probably 
among the most common cause of primary degenerative dementia even in other 
clinical settings. DLB can be diagnosed reliably with the revised clinical criteria and 
clinical instruments like the NPI, fluctuation inventories, UPDRS-3 and MSQ. Cut-off 
scores on these scales are provided and can now be applied in other clinical settings 
like nursing homes, general practice and hospitals. Sleep disturbances in mild 
dementia are common in DLB and correlated with anxiety and depression and as a 
consequence should be screened for and treated in the clinic. Clinicians seeing patients 
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with dementia need to systematically screen for visual hallucinations, cognitive 
fluctuations, parkinsonism and RBD to diagnose DLB.
Directions for future research 
In DLB the sensitivity and specificity of the revised DLB criteria as compared to 
neuropathology need to be explored to determine if the specificity is acceptable and to 
determine their positive predictive value in different clinical settings. The stability of 
the core and suggestive features of DLB over time needs to be explored, in particular 
the clinical course of patient fulfilling the criteria for possible DLB need to be 
characterised.. Treatment studies of sleep disturbances and other clinical features in 
DLB with both pharmacological and non-pharmacological interventions are urgently 
needed. New biomarkers in CSF for diagnostic and prognostic purposes as well as for 
ultimately underpinning the development of future disease modifying interventions are 
needed. 
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Appendix 
Revised criteria for the clinical diagnosis of DLB 
1. Central feature (essential for a diagnosis of possible or probable DLB) 
• Dementia defined as progressive cognitive decline of sufficient magnitude to interfere 
with normal social or occupational function. 
• Prominent or persistent memory impairment may not necessarily occur in the early 
stages but is usually evident with progression. 
• Deficits on tests of attention, executive function, and visuospatial ability may be 
especially prominent. 
2. Core features (two core features are sufficient for a diagnosis of probable DLB, one 
for possible DLB.) 
• Fluctuating cognition with pronounced variations in attention and alertness. 
• Recurrent visual hallucinations that are typically well formed and detailed. 
• Spontaneous features of parkinsonism. 
3. Suggestive features (If one or more of these is present in the presents of one or more 
core features a diagnosis of probable DLB can be made. In the absence of any core 
features, one or more suggestive features is sufficient for possible DLB. Probable 
DLB should not be diagnosed on the basis of suggestive features alone.) 
• REM sleep behaviour disorder 
• Severe neuroleptic sensitivity 
• Low dopamine transporter uptake in basal ganglia demonstrated by SPECT or PET 
imaging. 
4. Supportive features (commonly present but not proven to have diagnostic specificity) 
• Repeated falls and syncope 
• Transient, unexplained loss of consciousness 
• Severe autonomic dysfunction, e.g. orthostatic hypotension, urinary incontinence. 
• Hallucinations in other modalities 
• Systematized delusions 
• Depression 
• Relative preservation of medial temporal lobe structures on CT/MRI scan 
• Generalized low uptake on SPECT/PET perfusion scan with reduced occipital activity 
• Abnormal (low uptake) MIBG myocardial scintigraphy 
5. A diagnosis of DLB is less likely 
• In the presence of cerebrovascular disease evident as focal neurologic signs or on 
brain imaging. 
• In the presence of any other physical illness or brain disorder sufficient to count in 
part or in total for the clinical picture 
• If parkinsonism only appears for the first time at a stage of severe dementia 
6. Temporal sequence of symptoms 
• DLB should be diagnosed when dementia occurs before or concurrently with 
parkinsonism (if it is presented). (Shortened, see reference (I. G. McKeith, et al., 
2005) for full text.) 
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